
Validation data for Raji-hPD-1 Cells

https://www.invivogen.com/raji-hpd1

For research use only Version 20C16-ED

Raji-hPD-1 cells were developed from the Raji cell line to overexpress the human programmed cell death 1 (PD-1, also known as CD279) gene. Raji-hPD-1 cells were designed as target cells in InvivoGen's antibody-dependent cellular cytotoxicity (ADCC) assay using clinically-relevant anti-human PD-1 monoclonal antibodies (mAbs). Human PD-1 expression by Raji-hPD-1 cells has been verified by flow-cytometry (Figure 1), and induction of ADCC has been validated using InvivoGen's combinations of anti-human PD-1 antibody isotypes and Jurkat-NFAT Lucia™ CD16 reporter cell line (Figure 2). The level of ADCC induction is measured as a bioluminescent signal produced by an NFAT-dependent Lucia luciferase reporter protein. Antibodies displaying lower EC₅₀ have higher ADCC potency.

Validation of PD-1 expression






Figure 1: Validation of the expression of human PD-1 by Raji-hPD-1 cells. Raji-Null (A) and Raji-hPD-1 (B) cells were incubated with a PE-conjugated Anti-hPD-1 mAb for 30 minutes. The binding affinity was then measured using flow cytometry.

ADCC assay using various anti-human PD-1 (Nivolumab) antibody isotypes and Raji-hPD-1 target cells




Figure 2: Comparison of ADCC potency for native and engineered anti-human PD-1 antibody isotypes. Raji-hPD-1 cells were incubated with gradient concentrations of Anti-hPD-1 or Anti- β -galactosidase (β -gal) mAbs for 1 hour. Jurkat-LuciaTM NFAT-CD16 effector cells were then co-incubated with targets cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-LucTM. Percentages of the maximal response normalized to the IgG1 isotype are shown.



E-mail: info@invivogen.com